Respiratory Epidemiology and Clinical Research Unit, Research Institute of McGill University Health Centre, McGill University, Montreal, Canada.
Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Canada.
BMJ Open. 2017 Dec 21;7(12):e018954. doi: 10.1136/bmjopen-2017-018954.
During the last decade, many articles have been published, including reviews on fractional exhaled nitric oxide (FeNO) use and utility in clinical practice and for monitoring and identifying eosinophilic airway inflammation, especially in asthma, and evaluating corticosteroid responsiveness. However, the exact role of FeNO in patients with chronic obstructive pulmonary disease (COPD) and its ability to distinguish patients with COPD and those having concomitant asthma, that is, asthma-COPD overlap (ACO) is still unclear and needs to be defined. Due to the broad topics of FeNO in chronic airway disease, we undertook a scoping review. The present article describes the protocol of a scoping review of peer-reviewed published literature specific to FeNO in COPD/ACO over the last decade.
We used Joanna Briggs Institute Reviewers' Manual scoping review methodology as well as Levac 's and Arksey 's framework as guides. We searched a variety of databases, including Medline, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, Web of Science, and BioSciences Information Service (BIOSIS) on 29 June 2016. Additional studies will be recognised by exploring the reference list of identified eligible studies. Screening of eligible studies will be independently performed by two reviewers and any disagreement will be solved by the third reviewer. We will analyse the gathered data from article bibliographies and abstracts.
To investigate the body of published studies regarding the role of FeNO in patients with COPD and its usefulness in the clinical setting, a scoping review can be used as a modern and pioneer model, which does not need ethics approval. By this review, new insights for conducting new research specific to FeNO in COPD/ACO population will emerge. The results of this study will be reported in the scientific meetings and conferences, which aim to provide information to the clinicians, primary care providers and basic science researchers.
在过去的十年中，已经发表了许多文章，包括关于呼出气一氧化氮（FeNO）的使用和在临床实践中的用途以及监测和识别嗜酸性气道炎症（尤其是在哮喘中）的综述，以及评估皮质类固醇反应性。然而，FeNO 在慢性阻塞性肺疾病（COPD）患者中的确切作用及其区分 COPD 患者和同时患有哮喘的患者（即哮喘-COPD 重叠（ACO））的能力仍不清楚，需要进一步明确。由于 FeNO 在慢性气道疾病中的广泛主题，我们进行了范围性审查。本文描述了一项针对过去十年中 COPD/ACO 中 FeNO 相关同行评审文献的范围性综述的方案。
我们使用了 Joanna Briggs 研究所审查员手册范围性审查方法以及 Levac 和 Arksey 的框架作为指导。我们于 2016 年 6 月 29 日在各种数据库中进行了搜索，包括 Medline、Embase、护理学和联合健康文献累积索引（CINAHL）、Cochrane 图书馆、Web of Science 和生物科学信息服务（BIOSIS）。通过探索确定的合格研究的参考文献列表，将识别出其他研究。两名评审员将独立筛选合格研究，如果存在分歧，将由第三名评审员解决。我们将从文章书目和摘要中分析收集的数据。
为了研究发表的关于 FeNO 在 COPD 患者中的作用及其在临床环境中的用途的研究文献，范围性综述可以作为一种现代和开创性的模型，无需伦理批准。通过这项综述，将为 COPD/ACO 人群中特定于 FeNO 的新研究提供新的见解。本研究的结果将在科学会议和研讨会上报告，旨在为临床医生、初级保健提供者和基础科学研究人员提供信息。
